Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report

Collapsing Focal Segmental Glomerulosclerosis and Acute Kidney Injury Associated With Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: A Case Report

Chimeric antigen receptor T (CAR-T) cell treatment is a rapidly emerging therapy for relapsed/refractory hematologic malignancies. Although cytokine release syndrome is a common complication, a concomitant development of biopsy-proven collapsing glomerulopathy and acute kidney injury (AKI) has not b...

Full description

Bibliographic Details
Main Authors:	Ratna Acharya, Biljana Horn, Xu Zeng, Kiran Upadhyay
Format:	Article
Language:	English
Published:	Elsevier 2021-11-01
Series:	Kidney Medicine
Subjects:	Chimeric antigen receptor T cells collapsing FSGS cytokine release syndrome acute kidney injury leukemia
Online Access:	http://www.sciencedirect.com/science/article/pii/S2590059521001710

Similar Items

COVID-19–Related Glomerulopathy: A Report of 2 Cases of Collapsing Focal Segmental Glomerulosclerosis
by: Sandeep Magoon, et al.
Published: (2020-07-01)

Focused evaluation of the roles of macrophages in chimeric antigen receptor (CAR) T cell therapy associated cytokine release syndrome
by: Hanfei Guo, et al.
Published: (2022-03-01)

Collapsing Focal Segmental Glomerulosclerosis in Siblings With Compound Heterozygous Variants in NUP93 Expand the Spectrum of Kidney Phenotypes Associated With Nucleoporin Gene Mutations
by: Rachel K. Cason, et al.
Published: (2022-07-01)

Case Report: Collapsing Focal Segmental Glomerulosclerosis After Initiation of Ado-Trastuzumab Emtansine Therapy
by: Samy Hakroush, et al.
Published: (2021-11-01)

Study of the morphologic variants of focal segmental glomerulosclerosis: a Brazilian report Estudo brasileiro das variantes morfológicas da glomerulosclerose segmentar e focal
by: Leonardo de Abreu Testagrossa, et al.
Published: (2012-06-01)

Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment
by: Antonio Nenna, et al.
Published: (2022-07-01)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
by: Yanyu Pang, et al.
Published: (2018-05-01)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
by: Zhiling Yan, et al.
Published: (2021-02-01)

Prediction of kidney survival in children with primary focal segmental glomerulosclerosis (a two-center study).
by: Alaleh Gheissari, et al.
Published: (2007-07-01)

Podocyte number and glomerulosclerosis indices are associated with the response to therapy for primary focal segmental glomerulosclerosis
by: Natasha de Zoysa, et al.
Published: (2024-03-01)

Focal Segmental Glomerulosclerosis and Recurrence in Living Donor Recipients
by: Mang J, et al.
Published: (2021-07-01)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
by: Michael M. Boyiadzis, et al.
Published: (2018-12-01)

Biomarkers in Primary Focal Segmental Glomerulosclerosis in Optimal Diagnostic-Therapeutic Strategy
by: Aleksandra Musiała, et al.
Published: (2022-06-01)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
by: Jin Zhou, et al.
Published: (2022-09-01)

Disease Recurrence—The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis
by: Katrin Kienzl-Wagner, et al.
Published: (2019-07-01)

Bone marrow mesenchymal stem cells attenuate the progression of focal segmental glomerulosclerosis in rat models
by: Ru-chun Yang, et al.
Published: (2018-11-01)

A new index for the outcome of focal segmental glomerulosclerosis
by: Liu Chan, et al.
Published: (2024-04-01)

Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
by: Utkarsh H. Acharya, et al.
Published: (2020-12-01)

Focal segmental glomerulosclerosis; collapsing variant
by: Peyman Mohammadi Torbati
Published: (2012-07-01)

Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T‐cell therapy recipients
by: Marissa Z. Powell, et al.
Published: (2023-04-01)

A study on influence of different signal peptides on anti-tumor effect of chimeric antigen receptor (CAR) T cells
by: LI Fan, ZHANG Qinxing, TONG Xiangwen, TIAN Gaohui, GU Lixing, XU Yao
Published: (2022-02-01)

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
by: Mingxue Fan, et al.
Published: (2017-08-01)

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
by: Yongxian Hu, et al.
Published: (2016-08-01)

Cervical Edema Extending to the Larynx as Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-Cell Therapy in a Boy with Refractory Acute Lymphoblastic Leukemia
by: Haruko Shima, et al.
Published: (2022-03-01)

Improving cell reinfusion to enhance the efficacy of chimeric antigen receptor T-cell therapy and alleviate complications
by: Zhihao Han, et al.
Published: (2024-04-01)

Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
by: Chieh Yang, et al.
Published: (2023-10-01)

Chimeric Antigen Receptor beyond CAR-T Cells
by: Vicky Mengfei Qin, et al.
Published: (2021-01-01)

Control effect of Dasatinib on the treatment of acute myeloid leukemia and adverse events of CD123 targeting CAR-T: a case report and literature review
by: LI Chunmin, et al.
Published: (2024-02-01)

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse
by: Lijuan Ding, et al.
Published: (2021-11-01)

Collapsing focal segmental glomerulosclerosis: Increasing the awareness
by: Muhammed Mubarak
Published: (2012-07-01)

CAR‐T‐OPENIA: Chimeric antigen receptor T‐cell therapy‐associated cytopenias
by: Alankrita Taneja, et al.
Published: (2022-01-01)

Cardiovascular disease and chimeric antigen receptor cellular therapy
by: Anjali Rao, et al.
Published: (2022-09-01)

A Study of Focal and Segmental Glomerulosclerosis according to the Columbia Classification and Its Correlation with the Clinical Outcome
by: Swapna Nuguri, et al.
Published: (2023-09-01)

Macrophage, the potential key mediator in CAR-T related CRS
by: Zhaonian Hao, et al.
Published: (2020-07-01)

Improved efficacy with early tocilizumab in the prophylaxis and treatment of cytokine release syndrome of chimeric antigen receptor T cell (CAR-T) therapy for diffuse large B-cell lymphoma than acute lymphoblastic leukemia
by: Chengxin Luan, et al.
Published: (2023-09-01)

Cardiovascular Complications of Chimeric Antigen Receptor T-Cell Therapy: The Cytokine Release Syndrome and Associated Arrhythmias
by: Cesar Clavijo Simbaqueba, et al.
Published: (2020-08-01)

T Cell Engaging Immunotherapies, Highlighting Chimeric Antigen Receptor (CAR) T Cell Therapy
by: Elien De Bousser, et al.
Published: (2021-12-01)

Timing of Tocilizumab Administration Under the Guidance of IL-6 in CAR-T Therapy for R/R Acute Lymphoblastic Leukemia
by: Yinqiang Zhang, et al.
Published: (2022-06-01)

Early recurrence of focal segmental glomerulosclerosis in kidney transplant recipients: When to consider regifting
by: Erika L. Wood, et al.
Published: (2023-06-01)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
by: Katie S. Gatwood, et al.
Published: (2022-01-01)